Preoperative inflammatory markers for predicting parathyroid carcinoma.
lymphocyte-to-monocyte ratio
parathyroid carcinoma
preoperative prediction
tumor size
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
19
05
2022
accepted:
13
06
2022
pubmed:
15
6
2022
medline:
15
6
2022
entrez:
14
6
2022
Statut:
epublish
Résumé
Parathyroid carcinoma is a rare tumor among parathyroid tumors. Aspiration cytology and needle biopsy are generally not recommended for diagnostic purposes because they cause dissemination. Therefore, it is commonly diagnosed by postoperative histopathological examination. In this study, we investigated whether preoperative inflammatory markers can be used as predictors of cancer in patients with primary hyperparathyroidism. This was a retrospective study. Thirty-six cases of parathyroid carcinoma and 50 cases of parathyroid adenoma (PA) operated with the diagnosis of primary hyperparathyroidism and confirmed histopathologically at Ito Hospital were included in this study. Preoperative clinical characteristics and inflammatory markers (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio (LMR)) were compared and their values in preoperative prediction were evaluated and analyzed. Preoperative intact-parathyroid hormone (P = 0.0003), serum calcium (P = 0.0048), and tumor diameter (P = 0.0002) were significantly higher in parathyroid carcinoma than in PA. LMR showed a significant decrease in parathyroid carcinoma (P = 0.0062). In multivariate analysis, LMR and tumor length diameter were independent predictors. In the receiver operating characteristics analysis, the cut-off values for LMR and tumor length diameter were 4.85 and 28.0 mm, respectively, for parathyroid cancer prediction. When the two extracted factors were stratified by the number of factors held, the predictive ability improved as the number of factors increased. In the preoperative evaluation, a combination of tumor length diameter of more than 28 mm and LMR of less than 4.85 was considered to have a high probability of cancer.
Identifiants
pubmed: 35700222
doi: 10.1530/EC-22-0062
pii: EC-22-0062
pmc: PMC9346317
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Cytokine. 2008 Sep;43(3):374-9
pubmed: 18701317
Gastroenterol Res Pract. 2016;2016:9801063
pubmed: 27594882
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Br J Cancer. 2014 Jan 21;110(2):435-40
pubmed: 24357796
N Engl J Med. 2011 Dec 22;365(25):2389-97
pubmed: 22187986
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Cancer Manag Res. 2018 Nov 22;10:6167-6179
pubmed: 30538564
Oncotarget. 2017 Sep 20;8(48):84506-84514
pubmed: 29137443
Clin Transl Oncol. 2018 Apr;20(4):476-483
pubmed: 28785911
BMC Cancer. 2018 Nov 19;18(1):1137
pubmed: 30453914
Clin Cancer Res. 2002 Aug;8(8):2553-62
pubmed: 12171883
Ann Surg Oncol. 2010 Aug;17(8):2156-74
pubmed: 20221704
Ann Surg Oncol. 2012 Aug;19(8):2620-8
pubmed: 22434247
Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):877-889
pubmed: 30551989
Endocr J. 2001 Apr;48(2):213-7
pubmed: 11456270
J Surg Oncol. 2017 May;115(6):718-728
pubmed: 28127774
Surgery. 2014 Nov;156(5):1132-44
pubmed: 25444314
Int Surg. 2015 Jul;100(7-8):1185-9
pubmed: 26595491
Med Oncol. 2014 Jul;31(7):70
pubmed: 24927957
FEBS Open Bio. 2015 Aug 07;5:682-7
pubmed: 26380812
Ann Surg Oncol. 2014 Jun;21(6):1891-7
pubmed: 24522991
Arch Med Sci. 2019 Jul;15(4):880-886
pubmed: 31360183
J Korean Med Sci. 2012 Aug;27(8):890-5
pubmed: 22876055
J Clin Endocrinol Metab. 2011 Dec;96(12):3679-86
pubmed: 21937626
Jpn J Radiol. 2019 May;37(5):380-389
pubmed: 30863971
Nat Rev Endocrinol. 2012 Oct;8(10):612-22
pubmed: 22751344
Leuk Lymphoma. 2012 Apr;53(4):575-80
pubmed: 22098403
J Am Coll Surg. 2015 Jun;220(6):1054-62
pubmed: 25488353
Front Horm Res. 2019;51:63-76
pubmed: 30641523
J Surg Res. 2020 Feb;246:535-543
pubmed: 31711613
Clin Endocrinol (Oxf). 2016 Jul;85(1):29-36
pubmed: 26939543
Arch Ital Urol Androl. 2019 Jan 17;90(4):270-275
pubmed: 30655640
World J Surg. 1991 Nov-Dec;15(6):738-44
pubmed: 1767540
Nat Genet. 2002 Dec;32(4):676-80
pubmed: 12434154
J Surg Res. 2008 Aug;148(2):143-51
pubmed: 18561948
Medicine (Baltimore). 2018 Dec;97(52):e13896
pubmed: 30593200
Int J Endocrinol. 2019 Dec 18;2019:1761030
pubmed: 31929790
Surgery. 2014 Dec;156(6):1622-9; discussion 1629-30
pubmed: 25456964
J Cancer Res Clin Oncol. 2008 Oct;134(10):1143-9
pubmed: 18347812
J Bone Miner Res. 2008 Dec;23(12):1869-80
pubmed: 19016595
Endocr Pathol. 2021 Mar;32(1):17-34
pubmed: 33269427
Surgery. 2014 Dec;156(6):1336-41; discussion 1341
pubmed: 25456903
J Cancer. 2021 Mar 5;12(9):2687-2693
pubmed: 33854628
Oncotarget. 2016 May 31;7(22):31926-42
pubmed: 26942464
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Br J Cancer. 2004 Jun 1;90(11):2053-8
pubmed: 15164120
Langenbecks Arch Surg. 2016 Nov;401(7):943-951
pubmed: 26658808
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Acta Radiol. 2017 Jun;58(6):670-675
pubmed: 27609904
Eur J Haematol. 2014 Mar;92(3):204-10
pubmed: 24283206